Location
Philadelphia, PA
Start Date
10-5-2021 12:00 AM
End Date
13-5-2021 12:00 AM
Description
Background: Prostate cancer (PCa) is one of the most widespread cancers diagnosed in men in the United States and is the second leading cause of cancer-related deaths worldwide. PCa will be a major cancer-related burden both socially and economically in the near future. It has been shown that dietary intake of natural anti-inflammatory agents are capable of inhibiting cancer progression, but due to the nature of dietary studies it is difficult to accurately conclude that diet is capable of impacting chronic diseases and mortality.This systematic review aims to collect and evaluate literature focused on prostate cancer progression and the natural anti-inflammatory agents of lycopene and the Mediterranean diet (MedD).
Data Sources: An electronic search included the following databases: PubMed, EBSCOhost Web, Scopus and clinical trials registry platforms were used to survey the important literature.
Study Selection: Study inclusion criteria were as follows: 1) uniform form of measurement for evaluating the risk of prostate cancer/ current state of prostate cancer in patients; 2) patients treated in a clinical or observational setting; 3) an experimental group in which subjects clearly underwent an intervention focused on preventing or reducing prostate cancer initiation or progression; 4) a clearly defined control group in which subjects received either a placebo or standard care therapy; and 5) an outcome measure assessing the risk or current state of prostate cancer.
Data Extraction: For randomized control trials a qualitative analysis was done to collate and summarize effects of identified interventions according to the recommended methodology from the Cochrane Handbook. For all other types of studies (Cohort Studies, Case-control studies, and Cross-sectional studies) a rubric of criteria that I created was used to analyze these studies.
Data Synthesis: There were 33 randomized control trials and two controlled clinical trials that met all inclusion and no exclusion criteria for the search concerning lycopene and prostate cancer. There was only 1 study that met all inclusion and no exclusion for the search concerning the MedD and prostate cancer for both randomized clinical trials and controlled clinical trials. All studies had some concern for bias; therefore, the Cochrane risk bias tool as well as a created rubric of criteria was used.
Conclusions: Given the fact that there were many high-quality studies done regarding the effect of lycopene on prostate cancer inhibition and progression, the evidence to date suggests that 1) using lycopene in a dose dependent manner may help inhibit prostate cancer initiation and progression. As of now there are not enough high-quality clinical investigations done to show evidence that the MedD is capable of inhabiting initiation or proliferation. In the future, more high-quality clinical investigations will need to be done before making this conclusion.
Embargo Period
6-7-2021
Effects of Lycopene and the Mediterranean Diet on Prostate Cancer: A Critical Analysis of the Data
Philadelphia, PA
Background: Prostate cancer (PCa) is one of the most widespread cancers diagnosed in men in the United States and is the second leading cause of cancer-related deaths worldwide. PCa will be a major cancer-related burden both socially and economically in the near future. It has been shown that dietary intake of natural anti-inflammatory agents are capable of inhibiting cancer progression, but due to the nature of dietary studies it is difficult to accurately conclude that diet is capable of impacting chronic diseases and mortality.This systematic review aims to collect and evaluate literature focused on prostate cancer progression and the natural anti-inflammatory agents of lycopene and the Mediterranean diet (MedD).
Data Sources: An electronic search included the following databases: PubMed, EBSCOhost Web, Scopus and clinical trials registry platforms were used to survey the important literature.
Study Selection: Study inclusion criteria were as follows: 1) uniform form of measurement for evaluating the risk of prostate cancer/ current state of prostate cancer in patients; 2) patients treated in a clinical or observational setting; 3) an experimental group in which subjects clearly underwent an intervention focused on preventing or reducing prostate cancer initiation or progression; 4) a clearly defined control group in which subjects received either a placebo or standard care therapy; and 5) an outcome measure assessing the risk or current state of prostate cancer.
Data Extraction: For randomized control trials a qualitative analysis was done to collate and summarize effects of identified interventions according to the recommended methodology from the Cochrane Handbook. For all other types of studies (Cohort Studies, Case-control studies, and Cross-sectional studies) a rubric of criteria that I created was used to analyze these studies.
Data Synthesis: There were 33 randomized control trials and two controlled clinical trials that met all inclusion and no exclusion criteria for the search concerning lycopene and prostate cancer. There was only 1 study that met all inclusion and no exclusion for the search concerning the MedD and prostate cancer for both randomized clinical trials and controlled clinical trials. All studies had some concern for bias; therefore, the Cochrane risk bias tool as well as a created rubric of criteria was used.
Conclusions: Given the fact that there were many high-quality studies done regarding the effect of lycopene on prostate cancer inhibition and progression, the evidence to date suggests that 1) using lycopene in a dose dependent manner may help inhibit prostate cancer initiation and progression. As of now there are not enough high-quality clinical investigations done to show evidence that the MedD is capable of inhabiting initiation or proliferation. In the future, more high-quality clinical investigations will need to be done before making this conclusion.